PREMIER: Lifestyle Interventions for Blood Pressure Control (PREMIER) - Catalog
PREMIER: Lifestyle Interventions for Blood Pressure Control (PREMIER)
HLB00540609a
PREMIER
PRE
False
True
True
Coded
False
Clinical Trial
Open BioLINCC Study
Adult
Behavioral: diet, sodium-restrictedBehavioral: diet, fat-restrictedBehavioral: exerciseBehavioral: diet, reducingBehavioral: alcohol drinking
2009-10-01
2010-10-29
2009-05-20
2006-05-08
1998-2004
DCVS
Heart
non-HIV
non-COVID
2211
0
No
No
No
Yes
Yes
Yes
Restrictions are related to genetic/non-genetic biospecimen use by research topic.
Heart Diseases
Hypertension
To determine the effect on blood pressure (BP) of 2 multicomponent, behavioral interventions.
Weight loss, sodium reduction, increased physical activity, and limited alcohol intake are established recommendations that reduce BP. The Dietary Approaches to Stop Hypertension (DASH) diet also lowers BP. To date, no trial has evaluated the effects of simultaneously implementing these lifestyle recommendations.
Randomized trial with enrollment at 4 clinical centers (January 2000-June 2001) among 810 adults (mean [SD] age, 50 [8.9] years; 62% women; 34% African American) with above-optimal BP, including stage 1 hypertension (120-159 mm Hg systolic and 80-95 mm Hg diastolic), and who were not taking antihypertensive medications.
Randomized controlled clinical trial that tested two behavioral interventions compared with an advice-only group over a period of 18 months. The two interventions promoted established recommendations that reduce BP. One intervention in addition promoted the DASH diet, which is rich in fruits, vegetables, and low-fat dairy products, and low in saturated fat, total fat, and cholesterol.
Individuals with above-optimal BP, including stage 1 hypertension, can make and largely sustain multiple lifestyle changes. These lifestyle changes lower BP, improve BP control, and may reduce cardiovascular disease risk. (JAMA 2003;289:2083-2093; Ann Intern Med 2006;144:485-495).
Buffy Coat
Plasma
Serum
Urine
The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.
-
Subjects
Premier A: 273
Premier B: 268
Premier C: 269
Last Modified: Aug. 25, 2015, 3:02 p.m. -
Age
PREMIER A
PREMIER B
PREMIER C
All
N
%
N
%
N
%
N
%
=< 30
2
0.73
6
2.24
3
1.12
11
1.36
31-35
12
4.40
8
2.99
11
4.09
31
3.83
36-40
22
8.06
21
7.84
26
9.67
69
8.52
41-45
53
19.41
37
13.81
44
16.36
134
16.54
46-50
74
27.11
69
25.75
49
18.22
192
23.70
51-55
50
18.32
57
21.27
63
23.42
170
20.99
56-60
25
9.16
40
14.93
41
15.24
106
13.09
61-65
19
6.96
20
7.46
20
7.43
59
7.28
66-70
12
4.40
7
2.61
5
1.86
24
2.96
>= 71
4
1.47
3
1.12
7
2.60
14
1.73
Last Modified: Aug. 25, 2015, 3:02 p.m. -
Sex
PREMIER A
PREMIER B
PREMIER C
All
N
%
N
%
N
%
N
%
Male
101
37.00
94
35.07
115
42.75
310
38.27
Female
172
63.00
174
64.93
154
57.25
500
61.73
Last Modified: Aug. 25, 2015, 3:02 p.m. -
Race
PREMIER A
PREMIER B
PREMIER C
All
N
%
N
%
N
%
N
%
non-Black
173
63.37
168
62.69
190
70.63
531
65.56
Black
100
36.63
100
37.31
79
29.37
279
34.44
Last Modified: Aug. 25, 2015, 3:02 p.m.
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
-
Material Types
Last Modified: Nov. 30, 2015, 2:08 p.m. -
General Freeze/Thaw Status
-
Visits (Vials)
Last Modified: March 25, 2021, 3:30 p.m. -
Visits (Subjects)
03/04/2019
Serum Total number of subjects Average volume (ml) per subject Baseline 806 4.58 6 Month 741 4.56 18 Month 751 4.24 Unknown 3 1.18 Plasma Total number of subjects Average volume (ml) per subject Baseline 804 2.84 6 Month 741 2.92 18 Month 750 2.90 Urine Total number of subjects Average volume (ml) per subject Baseline 802 15.14 6 Month 640 14.85 18 Month 688 18.98 Buffy Coat Total number of subjects Average vials per subject Baseline 791 1.00
Last Modified: March 4, 2019, 4:20 p.m.